Tango Therapeutics, Inc. (NASDAQ: TNGX) is a Healthcare company (Biotechnology) with a market capitalization of $3.6B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Tango Therapeutics, Inc. had a Maz Rating of 4.29 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.83), among the strongest in its sector; its weakest was Valuation (1.18), among the most expensive in its sector. The other factors: Financial Health 4.28 (above most of its sector); Growth 3.11 (around the middle of its sector); Profitability 2.82 (around the middle of its sector). The current rating is for members: log in to see it.
At $21.50, Tango Therapeutics, Inc. trades at 67.4x sales and 3.1x book value. Over the last twelve months it generated about $54M of revenue and a net loss of $143M. It runs a gross margin of 98.2%, an operating margin of -253.4% and a net margin of -229.9%. It shows return on equity of -25.7%, return on invested capital of -12.9% and a free cash flow yield of -4.0%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 50.82. Over the past 52 weeks the share price ranged from $7.49 to $34.39, with a beta of 1.22.
Tango Therapeutics, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 12 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.